These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25667415)

  • 1. Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.
    Elavazhagan S; Fatehchand K; Santhanam V; Fang H; Ren L; Gautam S; Reader B; Mo X; Cheney C; Briercheck E; Vasilakos JP; Dietsch GN; Hershberg RM; Caligiuri M; Byrd JC; Butchar JP; Tridandapani S
    J Immunol; 2015 Mar; 194(6):2786-95. PubMed ID: 25667415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
    Lu H; Dietsch GN; Matthews MA; Yang Y; Ghanekar S; Inokuma M; Suni M; Maino VC; Henderson KE; Howbert JJ; Disis ML; Hershberg RM
    Clin Cancer Res; 2012 Jan; 18(2):499-509. PubMed ID: 22128302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme.
    Kawaguchi Y; Kono K; Mizukami Y; Mimura K; Fujii H
    Anticancer Res; 2009 Jun; 29(6):2137-46. PubMed ID: 19528474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.
    Philbin VJ; Dowling DJ; Gallington LC; Cortés G; Tan Z; Suter EE; Chi KW; Shuckett A; Stoler-Barak L; Tomai M; Miller RL; Mansfield K; Levy O
    J Allergy Clin Immunol; 2012 Jul; 130(1):195-204.e9. PubMed ID: 22521247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.
    Koch T; Derer S; Staudinger M; Rossen K; Glorius P; Peipp M; Kellner C; Kunzendorf U; Valerius T; Dechant M
    Am J Nephrol; 2013; 38(5):379-87. PubMed ID: 24157422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.
    Cifaldi L; Prencipe G; Caiello I; Bracaglia C; Locatelli F; De Benedetti F; Strippoli R
    Arthritis Rheumatol; 2015 Nov; 67(11):3037-46. PubMed ID: 26251193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
    Butchar JP; Mehta P; Justiniano SE; Guenterberg KD; Kondadasula SV; Mo X; Chemudupati M; Kanneganti TD; Amer A; Muthusamy N; Jarjoura D; Marsh CB; Carson WE; Byrd JC; Tridandapani S
    Clin Cancer Res; 2010 Apr; 16(7):2065-75. PubMed ID: 20332325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
    Beesu M; Caruso G; Salyer AC; Shukla NM; Khetani KK; Smith LJ; Fox LM; Tanji H; Ohto U; Shimizu T; David SA
    J Med Chem; 2016 Apr; 59(7):3311-30. PubMed ID: 26966993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity.
    Sanchez-Martínez D; Krzywinska E; Rathore MG; Saumet A; Cornillon A; Lopez-Royuela N; Martínez-Lostao L; Ramirez-Labrada A; Lu ZY; Rossi JF; Fernández-Orth D; Escorza S; Anel A; Lecellier CH; Pardo J; Villalba M
    Int J Biochem Cell Biol; 2014 Apr; 49():42-52. PubMed ID: 24440757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8.
    Döring Y; Hurst J; Lorenz M; Prinz N; Clemens N; Drechsler MD; Bauer S; Chapman J; Shoenfeld Y; Blank M; Lackner KJ; von Landenberg P
    Immunobiology; 2010 Mar; 215(3):230-41. PubMed ID: 19457574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans.
    Ayithan N; Ghosh A; Dwivedi A; Wallin JJ; Tan SK; Chen D; Kottilil S; Poonia B
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol consumption decreases IL-2-induced NF-kappaB activity in enriched NK cells from C57BL/6 mice.
    Zhou J; Meadows GG
    Toxicol Sci; 2003 May; 73(1):72-9. PubMed ID: 12700414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of TLR8 in human cervical cancer HeLa cells and the effect of TLR8 agonist on the cell proliferation and apoptosis].
    Yang H; He ZQ; Zhao YX; Wang KW; Zheng D; Su ZL; Tong J; Ma J; Wang SJ; Xu HX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):643-8. PubMed ID: 22340042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
    Berger M; Ablasser A; Kim S; Bekeredjian-Ding I; Giese T; Endres S; Hornung V; Hartmann G
    J Immunother; 2009 Apr; 32(3):262-71. PubMed ID: 19242374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.